DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20162484

Comparative evaluation of different doses of ciprofloxacin alone and in combination with sulfasalazine in experimentally induced inflammatory bowel disease in rats

Shivashankar Parashuram, Purushotham Krishna, Mangala Lahkar

Abstract


Background: Inflammatory bowel disease (IBD) is an idiopathic, chronic inflammatory condition, which affects the gastrointestinal tract and has no curative treatment. The present study aimed to investigate the effect of different doses of ciprofloxacin alone and in combination with sulfasalazine in AA (acetic acid)-induced inflammatory bowel disease (IBD) in rats.

Methods: A total of 36 animals were included in the study. Animals were divided into five groups (n = 6): group I - control (normal saline), group II-AA+ normal saline, group III-sulfasalazine(360mg/kg) +AA, group IV A - ciprofloxacin (50 mg/kg), group IV B- ciprofloxacin 100 mg/kg + AA, group V - ciprofloxacin 100 mg/kg + sulfasalazine (360 mg/kg) +AA. Group IV was divided into two subgroups, namely IVA and IVB, on the basis of different doses of ciprofloxacin used. After completion of two weeks of treatment, rats were sacrificed under ether anaesthesia for assessment of intestinal inflammation using parameters namely colon weight change, macroscopic and histopathological evaluation.

Results: There was a decrease in colonic weight, macroscopic scores and microscopic scores in groups treated with ciprofloxacin at a dose of 100 mg/kg i.e. high dose given alone and in combination with sulfasalazine. Combination treatment was more effective when compared to single drug treatment.

Conclusions: The present study indicates the efficacy of ciprofloxacin in acetic acid-induced IBD. The effects are more pronounced at higher dose i.e., 100 mg/kg. Combination of ciprofloxacin and sulfasalazine has shown greater efficacy than single drug treatment.


Keywords


Inflammatory bowel disease, Ciprofloxacin, Colon weight change, macroscopic evaluation, histopathological evaluation

Full Text:

PDF

References


Friedman S, Blumberg S. Inflammatory bowel disease. In: Kasper DL, Braunwald U, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of Internal medicine, 18th Ed, McGraw-Hill; 2012:1776-1788.

Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-29.

Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-31.

Palmer KR, Penman ID. Disease of the alimentary tracts and pancreas. In: Davidson’s principle and practice of medicine, Eds. Haslett C, Chilvers ER, Hunter JAA, Boon NA, 18th edn., Churchill Livingstone, UK; 1999:659-668.

Kenneth M, Mc Quid MD. Alimentary tract. In: Current Medical Diagnosis and Treatment. 42nd edn., Eds. Tierney LM, Macphee SJ, Papadakis MA, McGraw Hill, Chicago; 2003:602-611.

Bruton LL, Lazo JS, Parker KL. Goodman and Gilman’s The Pharmacologic Basis of Therapeutics. 12th edition. New York: Mc Graw Hill Publishers; 2011.

Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066-78.

Medhi B, Prakash A, Avti PK, Saikia UN, Pandhi P, Khanduja KL. Effect of manuka honey and sulfasalazine in combination to promote antioxidant defense system in experimentally induced ulcerative colitis model in rats. Indian Journal of Experimental Biology. 2008;46:583-90.

Kelly DE, Kaita, Assy N, Gauthier T, Zhang M, Adrienne FAM, et al. The beneficial effects of ciprofloxacin on survival and hepatic regenerative activity in a rat model of fulminant hepatic failure. Hepatology. 1998;27:2.

MacPherson BR, Pfeiffer CJ. Experimental production of diffuse colitis in rats. Digestion. 1978;17:135-50.

Choudhary S, Keshavarzian A, Yong S, Wade M, Bocckino S, Day BJ, et al. Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats. Dig Dis Sci. 2001;46:2222-30.

Morris GP, Beck PL, Herridge MS, Depew WT, Szewezuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795-803.

Weir RF. A new use for the useless appendix in surgical treatment of obstinate colitis. Med Rec. 1902;62:201.

Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344-67.

Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Infer S, Ghazanfari G, et al. Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. E CAM. 2007;4(1):43-50.

Lahat G, Halperin D, Barazovsky E, Shalit I, Rabau M, Klausner J, et al. Immunomodulatory effects of ciprofloxacin in TNBS-induced mice. Inflamm Bowel Dis. 2007;13(5):557-65.

Rath HC, Schultz M, Freitag R, Dieleman LA, Li FL, Linde HJ, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun. 2001;69:2277-85.

Kilic FS, Batu O, Yildirim E, Erol K, Deliorman S, Uyar R. Ciprofloxacin and pefloxacin suppress the inflammatory response in rats. Journal of Health Science. 2003;49(5):391-4.

Sachse F, Von Eiff C, Becker K, Rudack C. Anti-inflammatory effects of ciprofloxacin in S. aureus Newman induced nasal inflammation in vitro. Journal of Inflammation. 2008;5:11.

Remund K, Rechsteiner T, Rentsch K, Vogt P, Russi EW, Boehler A. Attenuation of airway obliteration by ciprofloxacin in experimental post-transplant bronchiolitis obliterans. Transplantation. 2008;85(5):726-31.